Ascendis Pharma AS (NAS:ASND)
$ 151.26 -2.17 (-1.41%) Market Cap: 8.67 Bil Enterprise Value: 9.12 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 74/100

Q1 2019 Ascendis Pharma A/S Earnings and Business Update Call Transcript

May 30, 2019 / 08:30PM GMT
Release Date Price: $128.44 (+0.43%)
Operator

Good day, ladies and gentlemen, and welcome to the First Quarter 2019 Ascendis Pharma Earnings Conference Call. (Operator Instructions) As a reminder, this call will be recorded.

I would now like to introduce your host for today's conference, Mr. Scott Smith, Senior Vice President and Chief Financial Officer of Ascendis Pharma. You may begin.

Scott T. Smith;S;CFO
Ascendis Pharma A;Senior VP & Member of Executive Board

/- -

Thank you, operator. Thank you, everyone, for joining our first quarter 2019 financial results conference call today. I'm Scott Smith, Chief Financial Officer of Ascendis. Joining me on today's call is Jan Mikkelsen, President and Chief Executive Officer; and Dr. Jonathan Leff, Chief Medical Officer.

Before we begin, I would like to remind you that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act. Examples of such statements may include but are not limited to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot